ReviewCureus2025
A Comprehensive Review of the Clinical Evidence on the Efficacy, Effectiveness, and Safety of Silodosin for the Treatment of Benign Prostatic Hyperplasia.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug- and patient-specific neurological risk profiles of α1-adrenergic blockers: evidence from FAERS and external validation in JADER.Therapeutic advances in drug safety · 2026Article
- Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management.Journal of personalized medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silodosin, a highly selective α1A-adrenoceptor blocker, is an effective treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Despite its growing use, there remains a lack of comprehensive evidence evaluating the efficacy/effectiveness and safety of silodosin in BPH patients, especially in patients with comorbidities. This review aimed to synthesize recent clinical evidence on the efficacy/effectiveness and overall safety of silodosin in treating BPH. The PubMed literature search identified 23 articles (clinical trials: n = 18; observational studies: n = 5) published between 2014-2024 for inclusion. Silodosin alone (n = 4) significantly improved urological outcomes and alleviated LUTS in BPH patients. In total, 19 studies examined the efficacy/effectiveness of silodosin compared with placebo (n = 2) or various pharmacological treatments (n = 17) for BPH, including other α1-adrenoceptor blockers and combination therapies. Silodosin reduced nocturia in BPH patients (n = 5). In BPH patients with comorbidities such as heart diseases, silodosin alleviated LUTS and enhanced quality of life (n = 5). Across 21 studies evaluating safety, silodosin was well-tolerated; the frequency of retrograde ejaculation/ejaculatory disorder ranged from 0.85% to 34.4%. Notably, the selective action of silodosin on α1A-adrenergic receptors was associated with minimal cardiovascular adverse events. This review demonstrated that silodosin is efficacious/effective and well-tolerated in BPH patients, including patients with cardiovascular comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.